Procter & Gamble Q2 Earnings: Rising Costs Squeeze Margins

Procter & Gamble (P&G) is often viewed as a global economic bellwether. As the titan behind ubiquitous household names like Tide, Pampers, and Gillette, its financial health offers a glimpse into the state of the consumer wallet. In their latest 10-Q filing for the quarter ended December 31, 2025, P&G revealed a mixed picture: while top-line sales managed to inch upward, the company faced significant pressure on its profitability due to rising costs and restructuring efforts.

Let’s dig into the income statement to see exactly where the money is coming from and where it is going.

Note: In the visualization above, you will notice a "Revenue not allocated to divisions" item of $160 million. This represents "Corporate" net sales, which generally includes adjustments or incidental revenue not directly tied to P&G's five primary business sectors.

The Top-Line Struggle and Margin Compression

For the quarter, P&G reported Net Sales of $22.2 billion, a modest 1% increase compared to the same period last year. This growth was driven primarily by higher pricing and favorable foreign exchange impacts, which helped offset a 1% decline in shipment volume. Essentially, P&G sold slightly fewer items but charged more for them (or benefited from currency conversion).

However, the real story lies further down the income statement. Net Earnings fell 7% to $4.3 billion, and Diluted Earnings Per Share (EPS) dropped 5% to $1.78.

What caused this profit squeeze? The filing highlights a few specific headwinds that eroded Gross Margin (the difference between sales and the cost of goods sold) by 120 basis points to 51.2%:

1. Unfavorable Product Mix: Consumers bought products with lower profit margins.
2. Restructuring Costs: The company is actively reorganizing certain markets and supply chains, incurring charges that weighed on the quarter.
3. Tariffs: Notably, higher tariff costs negatively impacted margins by 60 basis points.

While manufacturing productivity savings helped offset some of these issues, it wasn't enough to prevent a slide in operating income.

Segment Spotlight: Beauty and Health vs. Family Care

P&G operates through five main segments, and their performance was divergent this quarter.

• The Winners: The Beauty segment (Head & Shoulders, Olay) and Health Care segment (Crest, Vicks) both saw strong sales growth of 5%. Health Care was particularly boosted by the respiratory category, likely due to the cold and flu season driving demand for products like Vicks.
• The Middle Ground: Grooming (Gillette, Braun) saw a respectable 2% sales increase, while the massive Fabric & Home Care segment (Tide, Ariel)—which accounts for over a third of total company sales—grew just 1%.
• The Laggard: The Baby, Feminine & Family Care segment (Pampers, Bounty, Charmin) struggled, with sales falling 3%. This decline was driven by lower volumes, suggesting consumers might be trading down to cheaper alternatives or private-label brands in these essential categories.

"Core" vs. "Reported" Earnings

Financial filings often contain "Non-GAAP" measures, which are adjusted figures that companies believe better reflect their ongoing business performance. P&G emphasized its "Core EPS," which excludes the impact of the restructuring charges mentioned earlier.

While GAAP EPS fell to $1.78, Core EPS held steady at $1.88, flat compared to the prior year. This suggests that without the one-time costs of reorganizing the business, P&G's profitability would have remained stable.

Conclusion

This quarter highlights the defensive nature of Procter & Gamble, but also the challenges of growing a giant in a constrained economic environment. While the company continues to return massive amounts of cash to shareholders—$2.5 billion in dividends and $2.3 billion in share repurchases this quarter alone—it is fighting against volume declines and rising input costs.

As P&G navigates these headwinds, it faces stiff competition from rivals like Unilever and Kimberly-Clark, as well as retailer-owned private labels. The company’s ability to innovate in its high-margin Beauty and Health Care segments while managing costs in its commodity-sensitive Family Care business will be crucial for the quarters ahead.